Correction: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)

Ferah Comert Onder; Nermin Kahraman; Esen Bellur Atici; Ali Cagir; Hakan Kandemir; Gizem Tatar; Tugba Taskin Tok; Goknur Kara; Bekir Karliga; Serdar Durdagi; Mehmet Ay; Bulent Ozpolat

doi:10.1021/acsptsci.1c00113

Correction: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)

Ferah Comert Onder, Nermin Kahraman, Esen Bellur Atici, Ali Cagir, Hakan Kandemir, Gizem Tatar, Tugba Taskin Tok, Goknur Kara, Bekir Karliga, Serdar Durdagi, Mehmet Ay, Bulent Ozpolat

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

The corrections of misnumbered refs citations in the main text for refs 36-55 are given below. The changes in the reference list have not affected any conclusions reached in the paper.

Original language	English (US)
Pages (from-to)	1247
Number of pages	1
Journal	ACS Pharmacology and Translational Science
Volume	4
Issue number	3
DOIs	https://doi.org/10.1021/acsptsci.1c00113
State	Published - Jun 11 2021

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1021/acsptsci.1c00113

Fingerprint

Dive into the research topics of 'Correction: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)'. Together they form a unique fingerprint.

Cite this

Comert Onder, F., Kahraman, N., Bellur Atici, E., Cagir, A., Kandemir, H., Tatar, G., Taskin Tok, T., Kara, G., Karliga, B., Durdagi, S., Ay, M., & Ozpolat, B. (2021). Correction: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030). ACS Pharmacology and Translational Science, 4(3), 1247. https://doi.org/10.1021/acsptsci.1c00113

Correction: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030). / Comert Onder, Ferah; Kahraman, Nermin; Bellur Atici, Esen et al.
In: ACS Pharmacology and Translational Science, Vol. 4, No. 3, 11.06.2021, p. 1247.

Research output: Contribution to journal › Comment/debate › peer-review

Comert Onder, F, Kahraman, N, Bellur Atici, E, Cagir, A, Kandemir, H, Tatar, G, Taskin Tok, T, Kara, G, Karliga, B, Durdagi, S, Ay, M & Ozpolat, B 2021, 'Correction: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)', ACS Pharmacology and Translational Science, vol. 4, no. 3, pp. 1247. https://doi.org/10.1021/acsptsci.1c00113

Comert Onder F, Kahraman N, Bellur Atici E, Cagir A, Kandemir H, Tatar G et al. Correction: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030). ACS Pharmacology and Translational Science. 2021 Jun 11;4(3):1247. doi: 10.1021/acsptsci.1c00113

Comert Onder, Ferah ; Kahraman, Nermin ; Bellur Atici, Esen et al. / Correction : Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030). In: ACS Pharmacology and Translational Science. 2021 ; Vol. 4, No. 3. pp. 1247.

@article{4a2bfb2b1db34874a15e58d3532ca03b,

title = "Correction: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)",

abstract = "The corrections of misnumbered refs citations in the main text for refs 36-55 are given below. The changes in the reference list have not affected any conclusions reached in the paper.",

author = "\{Comert Onder\}, Ferah and Nermin Kahraman and \{Bellur Atici\}, Esen and Ali Cagir and Hakan Kandemir and Gizem Tatar and \{Taskin Tok\}, Tugba and Goknur Kara and Bekir Karliga and Serdar Durdagi and Mehmet Ay and Bulent Ozpolat",

note = "Publisher Copyright: {\textcopyright} 2021 American Chemical Society.",

year = "2021",

month = jun,

day = "11",

doi = "10.1021/acsptsci.1c00113",

language = "English (US)",

volume = "4",

pages = "1247",

journal = "ACS Pharmacology and Translational Science",

issn = "2575-9108",

publisher = "American Chemical Society",

number = "3",

}

TY - JOUR

T1 - Correction

T2 - Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)

AU - Comert Onder, Ferah

AU - Kahraman, Nermin

AU - Bellur Atici, Esen

AU - Cagir, Ali

AU - Kandemir, Hakan

AU - Tatar, Gizem

AU - Taskin Tok, Tugba

AU - Kara, Goknur

AU - Karliga, Bekir

AU - Durdagi, Serdar

AU - Ay, Mehmet

AU - Ozpolat, Bulent

PY - 2021/6/11

Y1 - 2021/6/11

N2 - The corrections of misnumbered refs citations in the main text for refs 36-55 are given below. The changes in the reference list have not affected any conclusions reached in the paper.

AB - The corrections of misnumbered refs citations in the main text for refs 36-55 are given below. The changes in the reference list have not affected any conclusions reached in the paper.

UR - https://www.scopus.com/pages/publications/85106566787

UR - https://www.scopus.com/inward/citedby.url?scp=85106566787&partnerID=8YFLogxK

U2 - 10.1021/acsptsci.1c00113

DO - 10.1021/acsptsci.1c00113

M3 - Comment/debate

AN - SCOPUS:85106566787

SN - 2575-9108

VL - 4

SP - 1247

JO - ACS Pharmacology and Translational Science

JF - ACS Pharmacology and Translational Science

IS - 3

ER -

Correction: Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth in Vivo (ACS Pharmacol. Transl. Sci. (2021) 4:2 (926-940) DOI: 10.1021/acsptsci.1c00030)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this